Show notes
In this edition, blood-based concussion diagnostic tool gets patent; examining the brain’s electrical signals may be key to treating epilepsy, schizophrenia; machine-learning model may predict best antiseizure medications and more.
Read the full coverage here:
Neurolytixs secures US patent for blood-based concussion diagnostic tool
Examination of brain’s electrical signals may be key to treating epilepsy, schizophrenia
Machine-learning model may predict which antiseizure medications work best
Rafa receives FDA approval for autoinjector to treat status epilepticus in adults
Aptinyx completes enrollment of phase 2 trial for oral cognitive impairment treatment
References:
Hakeem H, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2514.
